Albertsen PC et al. 2005. 20-year outcomes following conservative management of clinically localized prostate cancer. JAMA, 293 (17), 2095-2101.
Bartsch G. et al., 2001. Prostate cancer mortality after introduction of prostate-specific antigen mass screening in the federal state of Tyrol, Austria. Urology, 58, 417-424.
Bill-Axelson A. et al. 2005. Radical prostatectomy versus watchful waiting in early prostate cancer. N. England J. Med.352 (19), 1977-1984.
Catalona WJ. et Loeb S. 2005. The PSA era is not over for prostate cancer. Europ. Urol., 48, 541-545.
Eggener SE. et al., 2005. Predictors of subsequent prostate cancer in men with a prostate-specific antigen of 2.6 to 4.0 ng/ml and an initially negative biopsy. J. Urol., 174, 500-504.
Khan MA et Partin AW. 2005. Expectant management : an option for localized prostate cancer. Prostate Cancer and prostatic diseases. 1-5.
Klotz L. 2004. Active surveillance with selective delayed intervention: using natural history to guide treatment in good risk prostate cancer. J. Urol., 172, S48-S51.
Malins D. et al. 2003. Cancer-related changes in prostate DNA as men age and early identification of metastasis in primary prostate tumors. Proc. Nat. Acad. Sci., 100 (9), 5401-5406.
Murphy AM. et al., 2004. Controversies in prostate cancer screening. J. Urol. 172, 1822-1824.
Naya Y. et al., 2003. Volume indexes of total, free, and complexed prostate-specific antigen enhance prediction of extraprostatic disease extension in men with nonpalpable prostate cancer. Urology 62, 1058-1062.
Partin A. et al. 2003. Complexed prostate specific antigen improves specificity for prostate cancer detection : results of a prospective multicenter clinical trial. J. Urol. 170, 1787-1791.
Raaijmakers R. et al. 2002. Complication rates and risk factors of 5802 transrectal ultrasound-guided sextant biopsies of the prostate within a population-based screening program. Urology 60, 826-830.
Potter S. et al., 2001. Age, prostate-specific antigen, and digital rectal examination as determinants of the probability of having prostate cancer. Urology, 57, 1100-1104.
Sakr WA. et al., 1996. Age and racial distribution of prostatic intraepithelial neoplasia. Europ. Urol., 30, 138-144.
Sakr WA. et Partin A., 2001. Histological markers of risk and the role of high-grade prostatic intraepithelial neoplasia. Urology, 57 (Supp. 4A), 115-120.
Sanchez-Chapado M. et al. 2003. Prevalence of prostate cancer and prostatic intraepithelial neoplasia in Caucasian Mediterranean males: an autopsy study. The Prostate, 54, 238-247.
Singh H. et al. 2004. Improved detection of clinically significant, curable prostate cancer with systematic 12-core biopsy. J. Urol. 171, 1089-1092.
Soos G. et al., 2005. The prevalence of prostate carcinoma and its precursors in Hungary: an autopsy study. Europ. Urol.
Stamey T. et al. 2003. Genetic profiling of Gleason grade 4/5 prostate cancer: which is the best prostatic control tissue ? J Urol. 170, 2263-2268.
Stamey T. et al. 2004 et 2005. The prostate specific antigen era in the United States is over for prostate cancer: what happened in the last 20 years ? J. Urol, 172, 1297-1301 et 174, 1154-1156.
Thompson I. et al. 2004 Prevalence of prostate cancer among men with a prostate-specific antigen level < or = 4.0 ng per milliliter. New England J. Med. 350 (22), 2239-2246.
Verdecchia A. et al., 2002. A comparative study of cancer prevalence in cancer registry areas of France, Italy and Spain. Annals Oncol. 13, 1128-1139.
Watanabe M. et al., 2000. Comparative studies of prostate cancer in Japan versus the United States. A review. Urological Oncology, 5, 274-283.
Wang X. et al., 2005. Autoantibody signature in prostate cancer. N Eng J Med, 355 (12), 1224-1235.